Vibrational corrections to transition properties

The vibrational contributions to second-order transition properties are considered in the framework of the Born—Oppenheimer approximation. It is shown that the usual formula for vibrational second-order transition matrix elements is incomplete and needs to be supplemented by a term of purely vibrational origin. This pure vibrational contribution is calculated for vibrational transition polarizabilities in LiH and BeF and found to be quite significant. Its inclusion in theoretically calculated data for the Raman intensities appears to be necessary

Analytical dependence of substance solubility measure on temperature

ABSTRACT The work covers an adequate analytical dependence of solubility measure of the chemical substances on the water/aqueous solution temperature. The solubility was defined and new, more readable solubility measure was introduced; the coefficient of solubility has been proposed instead. Then the source differential equation was introduced as the basis for the derivation of a final analytical form of dependence of the solubility coefficient on temperature. That characteristics has been developed by determining the dependence of the solubility coefficient variability intensity on temperature. An example of the use of presented theory has been delivered by referring it to the phenomenon of dissolution of AgNO 3 silver nitrate in the aqueous environment. In the summary, quite a developed use of the source differential equation has been underlined with some more examples revealed

N-(2-Fluoro­phen­yl)-5-[(4-meth­oxy­phen­yl)amino­meth­yl]-6-methyl-2-phenyl­pyrimidin-4-amine

The conformation of the title mol­ecule, C25H23FN4O, is mainly determined by an intra­molecular N—H⋯N hydrogen bond closing a six-membered ring and the dihedral angles between the pyrimidine ring and the three benzene rings which are 12.8 (2), 12.0 (2) and 86.1 (2)°. An intra­molecular N—H⋯F inter­action also occurs. The crystal stucture is stabilized by weak C—H⋯O and C—H⋯π inter­actions. An inter­molecular N—H⋯N inter­action is also observed

The role of neuronal apoptosis inhibitory protein (NAIP) in acute myeloid leukemia patients

Acute myeloid leukemia (AML) is a heterogeneous, highly malignant neoplasm. Apoptosis is a complex process executed by caspases and suppressed by the inhibitor of apoptosis (IAP) family. Neuronal apoptosis inhibitory protein (NAIP), IAP’s member, may play an exceptional role in the mechanisms of tumors’ resistance to chemotherapy. The aims of the study were to assess the expression of NAIP in leukemic blasts of AML patients using flow cytometry and to evaluate its influence on disease outcome. NAIP expression was found in 106 out of 108 patients. A higher complete response rate was associated with a low expression of NAIP, age < 60 yo, and white blood cell count < 20 G/L ( = 0.009, = 0.033, and = 0.076, respectively) in univariate analyses and a low NAIP expression and age < 60 yo ( = 0.025 and = 0.013, respectively) in multivariate analyses. Longer overall survival (OS) in the univariate analysis was influenced by a low NAIP expression, age < 60 yo, and intensive chemotherapy ( = 0.033, < 0.001, and < 0.001, respectively). In the intensively treated group, better OS was observed in patients with age < 60 yo, AML, and a low NAIP expression ( = 0.03, = 0.024, and = 0.07, respectively). In multivariate analysis, longer OS was associated with age < 60 yo ( = 0.009) and AML ( = 0.007). In conclusion, we suggest that NAIP might play an adverse role in response to chemotherapy

Wtórna ostra białaczka szpikowa u chorej po skutecznym leczeniu ostrej białaczki promielocytowej

Clonal aberrations, leading to development of therapy-related myelodysplastic syndromes and secondary acute myeloid leukemias (s-AML), are present in 10% of patients treated previously for acute promyelocytic leukemia (APL). Most of them, especially monosomy 7, are associated with extremely poor prognosis. We present a case of 22-years-old female patient with APL diagnosed in 2008 who achieved complete cytogenetic and molecular remission after treatment according to PETHEMA protocol. Two years after the treatment was completed, s-AML with complex monosomal karyotype including monosomy 7 and t(3;21)(q26.2;q22) was diagnosed. Complete cytogenetic remission was achieved after 2 induction cycles and finally the allogeneic hematopoietic stem cell transplantation from HLA-matched related donor was performed. In the posttransplant period moderate chronic graft versus host disease was observed. Now, 15 months after transplantation, the patient is still in complete cytogenetic remission with 100% of donor chimerism. Presented case demonstrates diagnostic and therapeutic dilemma of s-AML in a patient with complete remission of APL.Klonalne aberracje chromosomalne, prowadzące do powstawania zespołów mielodysplastycznych rozwijających się po leczeniu lub wtórnych ostrych białaczek szpikowych (s-AML), występują u około 10% chorych leczonych w przeszłości z powodu ostrej białaczki promielocytowej (APL). Większość z nich, a w szczególności monosomia chromosomu 7, wiąże się z wybitnie niekorzystnym rokowaniem. W pracy przedstawiono przypadek 22-letniej chorej na APL rozpoznaną w 2008 roku, w całkowitej remisji cytogenetycznej i molekularnej po terapii według protokołu PETHEMA, u której 2 lata po zakończeniu leczenia APL rozpoznano s-AML ze złożonym kariotypem monoso­malnym, z obecnością między innymi monosomii chromosomu 7 i translokacji t(3;21)(q26.2;q22). Po 2 cyklach leczenia indukującego uzyskano całkowitą remisję cytogenetyczną i zakwalifikowano chorą do allogenicznego przeszczepienia krwiotwórczych komórek macierzystych od zgodnego dawcy rodzinnego. Okres okołoprzeszczepowy był powikłany przewlekłą chorobą przeszczep przeciw gospo­darzowi w stopniu umiarkowanym. Obecnie, 15 miesięcy po transplantacji, chora nadal pozostaje w całkowitej remisji cytogenetycznej ze 100-procentowym chimeryzmem donorowym. Opisany przypadek ilustruje złożony problem diagnostyczny i terapeutyczny s-APL u chorej w remisji po leczeniu APL

The role of bendamustine in chronic lymphocytic leukemia with particular focus on the treatment of elderly patients

Przewlekła białaczka limfocytowa (CLL) jest najczęstszą postacią białaczki diagnozowanej u osób dorosłych. Wybór schematu leczenia oraz jego intensywność powinny być dostosowane indywidualnie do każdego chorego, z których większość ma ponad 65 lat i często wiele schorzeń współistniejących. Bendamustyna (BEN) jest odkrytym na nowo cytostatykiem łączącym właściwości fizykochemiczne oraz farmakologiczne leków alkilujących i analogów purynowych. W niniejszym artykule skoncentrowano się na omówieniu właściwości BEN, analizie skuteczności tego leku w CLL oraz ocenie profilu bezpieczeństwa substancji i miejsca w leczeniu chorych na CLL.Chronic lymphocytic leukemia (CLL) is the most common form of leukemia diagnosed in adults. Selecting the proper treatment regimen, and its intensity should be adjusted individually for each patient — most of them are over 65 years-old and have often multiple comorbidities. Bendamustine (BEN) is rediscovered cytotoxic agent combining physicochemical and pharmacological properties of alkylating agents and purine analogues. This article focuses on the presentation of the substance, the analysis of effectiveness of BEN in CLL and the assessment of the drug safety profile and its role in the treatment of patients with CLL

Analysis of ibrutinib efficacy in a subgroup of chronic lymphocytic leukemia patients with 17p deletion: observational study of the Polish Adult Leukemia Group (PALG)

BackgroundThe 17p deletion is regarded as the strongest poor prognostic factor in chronic lymphocytic leukemia (CLL). Results of recently performed clinical trials have suggested that ibrutinib significantly improves the outcome in this patient group.AimThe study aimed at analyzing the efficacy and adverse events profile of ibrutinib monotherapy in CLL patients with 17p deletion treated in routine clinical practice outside clinical trials.Materials and MethodsClinical response and adverse events profile of ibrutinib monotherapy were assessed in thirty-five CLL patients with 17p deletion treated within the ibrutinib named patients program in Poland.ResultsOverall response rate was 80% (28/35 patients) with median observation time of 24.2 months (range 0,1 – 30,9). Complete remission was observed in 5 patients (14.3%), partial remission in 11 (31.4%), partial remission with lymphocytosis in 13 (37.1%), whereas stable disease and progression was noted in 4 (11.4%) and 1 (2.9%) respectively. Response was not assessed in 1 patient. Median progression-free survival was 29.5 months, whereas median overall survival was not reached. Eleven patients died (7 because of infection, 1 of CLL progression, 1 of sudden cardiac death, 1 of disseminated breast cancer and 1 of unknown causes). In 13 patients (37.1%) at least one 3 or 4 grade adverse event occurred. In 11 patients (31.4%) the treatment was temporary withheld or the dose reduced due to adverse events.ConclusionIbrutinib is characterized by high clinical efficacy and acceptable toxicity in CLL patients with 17p deletion in daily clinical practice

Forward-central two-particle correlations in p-Pb collisions at root s(NN)=5.02 TeV

Two-particle angular correlations between trigger particles in the forward pseudorapidity range (2.5 2GeV/c. (C) 2015 CERN for the benefit of the ALICE Collaboration. Published by Elsevier B. V.Peer reviewe